April 7, 2020

Ananda, LLC DBA Ananda Apothecary – 606163 – 04/06/2020

Product: Drugs Recipient: Recipient Name Mr. Scott Merrill Ananda, LLC DBA Ananda Apothecary 4735 Walnut St Ste EBoulder, CO 80301-2553United States [email protected] Date:               April 6, […]
April 7, 2020

Indigo Naturals – 606423 – 04/06/2020

Product: Drugs Date:                April 6, 2020 RE:                   Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19) This is to advise you that […]
April 7, 2020

Cathay Natural, LLC – 606161 – 04/06/2020

Product: Drugs Recipient: Recipient Name Ms. Cathay Fung Cathay Natural, LLC 1810 Summit StreetKansas City, MO 64108United States [email protected] Date:                April 6, 2020 RE:             […]
April 7, 2020

Enzymology Research Center, Inc. – 604613 – 03/26/2020

Product: Drugs Recipient: Recipient Name Troy A. Aupperle Recipient Title Owner and CEO Enzymology Research Center, Inc. 332 West Street N.Miltona, MN 56354-8256United States Issuing Office: […]
April 7, 2020

Global Treat Srl – 596638 – 03/31/2020

Delivery Method: VIA UPS Product: Drugs Recipient: Recipient Name Mr. Andrei Lisinschi Recipient Title General Manager/Owner Global Treat Srl Str. Portullui nr. 157, Floor 2, Suite […]
April 7, 2020

Fraudulent Activity and Unlawful Sales of Unapproved and Misbranded Drug Products | COVID-19

FDA considers the sale and promotion of fraudulent COVID-19 products to be a threat to the public health. We have a surveillance program that routinely monitors […]
April 7, 2020

Import of Drugs for Potential COVID-19 Treatment

FDA is working to address the COVID-19 pandemic by facilitating imports of drugs to potentially treat COVID-19. FDA is also working to protect Americans by monitoring […]
April 6, 2020

FDA approves luspatercept-aamt for anemia in adults with MDS

On April 3, 2020, the Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corporation) for the treatment of anemia failing an erythropoiesis stimulating agent and requiring […]
April 3, 2020

Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act

Docket Number: FDA-2014-D-0329 Issued by: Guidance Issuing Office Office of Medical Products and Tobacco, Center for Drug Evaluation and Research This guidance is intended for entities […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0